drugset / Trial / NCT02998242
Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer
Completed
40 enrolled
Sichuan Provincial People's Hospital
Chang'An Hospital · collabHainan Medical College · collab
Non-randomizedParallel-groupSingle-blindTreatment
Summary
To study safety and efficacy of apatinib in combination of radiotherapy in patients with symptomatic bony disease prostate cancer (SBPC), based on the potential synergistic antitumor activity between Apatinib and Stereotactic Body Radiation Therapy (SBRT).
Timeline
- Start
- 2016-05-10
- Primary completion
- 2017-01-05
- Completion
- 2017-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | — | Oral |
Indications
No indication recorded.